Results 61 to 70 of about 3,285,062 (216)

Optimization of the Treatment Protocol in Children with Gastroesophageal Reflux Disease

open access: yesZdorovʹe Rebenka, 2016
The article deals with the substantiation and assessment of the effectiveness of the inclusion of ursodeoxycholic acid preparation Ukrliv suspension in the treatment protocol of children with gastroesophageal reflux disease.
T.O. Kriuchko   +3 more
doaj   +1 more source

Ursodeoxycholic acid augmentation in treatment-refractory schizophrenia: a case report

open access: yesJournal of Medical Case Reports, 2020
Background Treatment-resistance is recognized as a significant dilemma in schizophrenia, which has been reported to involve approximately one-third of patients with schizophrenia.
Mohsen Khosravi
doaj   +1 more source

In Silico Prediction and Pharmacokinetic Comparison of Ursodeoxycholic Acid and Obeticholic Acid in the Management of Primary Biliary Cholangitis [PDF]

open access: yes, 2021
Background: Primary Biliary Cholangitis (PBC) is a persistent liver disease. Ursodeoxycholic acid is used as a first-line treatment for the past two decades.
Dhanasekaran, Dhivya   +7 more
core   +1 more source

The Role of Ursodeoxycholic Acid in Acute Viral Hepatitis: an Evidence-based Case Report

open access: yesActa Medica Indonesiana, 2015
Aim: to review the role of ursodeoxycholic acid in acute viral hepatitis. Methods: following literature searching according to the clinical question on Pubmed and Cochrane Library.
Indra Wijaya
doaj   +4 more sources

Biological synthesis of ursodeoxycholic acid

open access: yesFrontiers in Microbiology, 2023
Ursodeoxycholic acid (UDCA) is a fundamental treatment drug for numerous hepatobiliary diseases that also has adjuvant therapeutic effects on certain cancers and neurological diseases. Chemical UDCA synthesis is environmentally unfriendly with low yields.
Peng Song   +8 more
doaj   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt   +7 more
wiley   +1 more source

Effect of Combination Therapy with Atorvastatin and Ursodeoxycholic Acid on the Course of Ischemic Heart Disease with Co-Existent Non-Alcoholic Fatty Liver Disease and Obesity

open access: yesGalician Medical Journal, 2016
Non-alcoholic fatty liver disease is considered as an independent predictor of cardiovascular diseases which plays an important role in the development of ischemic heart disease. The drug most frequently used for treating this comorbidity is atorvastatin
Nataliya Karpyshyn
doaj   +1 more source

Successful treatment of an infant with congenital bile acid synthesis disorder type 3 by ursodeoxycholic acid: a case report

open access: yesJournal of Medical Case Reports, 2022
Background Congenital bile acid synthesis disorder type 3 caused by oxysterol 7α-hydroxylase deficiency is an extremely rare genetic liver disease. As it may cause rapid progression to end-stage liver disease, a high cautiousness in diagnosis and early ...
Weiqian Mo   +7 more
doaj   +1 more source

Hepatic sinusoidal obstruction syndrome and the search for a modifiable endothelial state

open access: yesiMeta, EarlyView.
Pyrrolizidine alkaloid (PA) exposure, haematopoietic stem cell transplantation (HSCT), and repeated oxaliplatin treatment provide distinct contexts for sinusoidal endothelial injury, with differing mechanisms and courses. Oxaliplatin‐associated abnormalities may resolve or persist. Illustrated features are conceptual, not validated clinical stages or a
Ziming Zhao   +13 more
wiley   +1 more source

Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis

open access: yes, 2017
Doxycycline has been shown to disrupt transthyretin amyloid (ATTR) fibrils [1] and tauro-ursodeoxycholic acid (TUDCA) has been shown to reduce TTR toxic aggregates in mice [2]. Further, in 2010 Cardoso et al.
Lundgren, Hans-Erik,   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy